Skip to main content

Table 1 General characteristics of the population included in the study

From: Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes

  NHIS NHIS + Eze HIS HIS + Eze p value*
N = 27,795 (74%) N = 2815 (7%) N = 6578 (17%) N = 645 (2%)
Age in years mean (S.D.) 72.6 (11) 69.4 (11) 71.7 (11) 66.9 (11)  < 0.001
Female n (%) 14,145 (51) 1202 (43) 2157 (33) 196 (30)  < 0.001
Age < 80 years n (%) 20,695 (75) 2411 (86) 5026 (76) 597 (93)  < 0.001
Hypertension n (%) 21,712 (78) 2296 (82) 5789 (88) 579 (90)  < 0.001
Diabetes n (%) 7718 (28) 772 (27) 1821 (28) 148 (23) N.S
GFR (ml/min/1.73 m2) mean (S.D.) 89.9 (31) 85.1 (30) 89.4 (32) 91.9 (31)  < 0.001
HbA1c (mmol/mol) mean (S.D.) 47.6 (13) 46.6 (12) 46.2 (13) 45.0 (12)  < 0.001
CVD n (%) 2592 (9) 573 (20) 1816 (28) 287 (45)  < 0.001
Cerebrovascular disease n (%) 2355 (9) 257 (9) 1838 (28) 72 (11)  < 0.001
Peripheral vascular disease n (%) 12 (0) N.I N.I 0 (0) N.S
Total-chol (mg/ml) mean (S.D.)a 167.8 (39) 162.4 (42) 145.1 (39) 145.3 (41)  < 0.001
LDL-chol (mg/dl) mean (S.D.)a 94.1 (32) 88.1 (35) 78.8 (31) 79.6 (35)  < 0.001
HDL-chol (mg/dl) mean (S.D.)a 52.8 (16) 51.8 (15) 46.8 (15) 47.3 (13)  < 0.001
Triglycerides (mg/dl) mean (S.D.)a 98.7 (62) 103.9 (69) 89.9 (64) 82.1 (52)  < 0.001
Non-HDL-chol (mg/dl) mean (S.D.)a 115.0 (35) 110.6 (39) 98.3 (35) 98 (39)  < 0.001
ACEi/ARB n (%) 17,097 (62) 1793 (64) 4570 (70) 472 (73)  < 0.001
Beta blockers n (%) 8923 (32) 1223 (43) 3482 (53) 435 (67)  < 0.001
CCB n (%) 6690 (24) 677 (24) 1716 (26) 138 (21)  < 0.01
Treat. Diabetes n (%) 7373 (27) 728 (26) 1665 (25) 134 (21)  < 0.01
Fibrates n (%) 185 (0.7) 31 (1.1) 50 (0.8) 5 (0.8) N.S
Simvastatin n (%) 10,350 (37.2) 44 (1.6) 0 (0.0) 0 (0.0)  
Lovastatin n (%) 840 (3.0) 30 (1.1) 0 (0.0) 0 (0.0)  
Pravastatin n (%) 1297 (4.7) 44 (1.6) 0 (0.0) 0 (0.0)  
Fluvastatin n (%) 256 (0.9) 5 (0.2) 0 (0.0) 0 (0.0)  
Atorvastatin n (%) 12,003 (43.2) 205 (7.3) 5864 (89.0) 516 (80.0)  
Rosuvastatin n (%) 3049 (11.0) 116 (4.1) 712 (11.0) 113 (17.5)  
Simvastatin + Ezetimibe n (%) 0 (0.0) 2363 (83.9) 0 (0.0) 0 (0.0)  
Rosuvastatin + Ezetimibe n (%) 0 (0.0) 8 (0.3) N.I 16 (2.5)  
  1. Data reported as mean (S.D.) or as n (%). Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
  2. HIS high-intensity statins, NHIS non-HIS, Eze ezetimibe
  3. *ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
  4. aAnalyses performed on patients with at least one detection before index